With the objective of reinforcing and expanding basic and clinical research on T1D, in late 2007 a specialized and independent research Institute – denominated Diabetes Research Institute (DRI) – was launched at San Raffaele. DRI is part of the International DRI federation (DRI-NET), which includes 12 other DRI’s around the world. The San Raffaele DRI is composed of six Units of Basic Research and five Groups of Clinical Research.
The overall objective of DRI is to prevent and cure T1D. To achieve this objective, two specific programs are pursued, both of which take advantage of patients and animal models:
Contact
San Raffaele Hospital – Milan, via Olgettina 60, 20132 Milan, Italy
Tel. 02 26 431
Having led a successful turnaround of the affiliate in just eight months, Nadia Cortesi of ResMed explains how she has achieved double digit growth, while facing sustained external challenges, including…
Despite the already existing efficiencies in the Italian healthcare system, there is still significant room for improvement. Johnson & Johnson Medical’s head for southern Europe discusses a number of opportunities…
3PL player BOMI Group went public via an IPO in June 2015. VP & CFO Marco Ruini discusses the reasons behind this Italian family company’s decision to go public, as well…
KPMG is committed to providing long-term support to public as well as private institutions as they tackle challenges and transform the way healthcare is provided. Alberto De Negri, partner of…
Angelini CEO Gianluigi Frozzi speaks about the company’s diverse portfolio of products, the “Made in Italy” brand, and the company’s continual global growth anchored strongly in innovation. Can you please give our…
As an emerging leader in mobile health and provider of innovative health-technologies, Philips is poised to provide Italian healthcare institutions with solutions that could enable significant gains in efficiency. CEO…
Biopharmaceutical logistics leader World Courier strives to understand their clients’ needs as early as possible, and the Italian affiliate has gone to unusual lengths, including joining the Italian biotech association,…
While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant…
Gnosis is a fully vertically integrated biotech company specialized in the manufacturing and sales of fermentation raw materials and natural finished products used in the pharmaceutical, nutraceutical, cosmetic, veterinary, and…
Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role…
Raffaele Stefanelli discusses the challenges of the medtech industry in Italy, the contribution of the Italian research community to Boston Scientific globally, and innovative partnership models. Could you introduce yourself…
Samsung is focused on the total digital transformation of medical services. It offers solutions in mobile health, hospital digitalization, and integrated medical and healthcare devices. The head of the healthcare…
See our Cookie Privacy Policy Here
